Zacks: Diffusion Pharmaceuticals Inc (DFFN) Receives Average Rating of “Strong Buy” from Brokerages
Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price objective of $10.00 for the company and are anticipating that the company will post ($0.69) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Diffusion Pharmaceuticals an industry rank of 72 out of 256 based on the ratings given to its competitors.
DFFN has been the subject of several recent research reports. ValuEngine downgraded Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. HC Wainwright upped their price target on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th.
Shares of NASDAQ:DFFN traded down $1.11 during trading on Friday, reaching $3.66. 469,121 shares of the stock were exchanged, compared to its average volume of 309,633. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.02. Diffusion Pharmaceuticals has a 1-year low of $1.83 and a 1-year high of $11.00. The firm has a market capitalization of $16.36 million, a price-to-earnings ratio of -0.60 and a beta of 0.21.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Equities research analysts anticipate that Diffusion Pharmaceuticals will post -2.27 earnings per share for the current fiscal year.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Read More: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.